Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results.

Autor:	Saeed A; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA; Department of Medicine, Division of Hematology and Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA. Electronic address: dranwaarsaeed1@gmail.com., Park R; Division of Hematology and Medical Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Dai J; Department of Biostatistics, Kansas University Medical Center, Kansas City, KS 66160, USA., Al-Rajabi R; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Kasi A; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Baranda J; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Williamson S; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA., Saeed A; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA., Ripp J; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA., Collins Z; Department of Radiology, Kansas University Medical Center, Kansas City, KS 66160, USA., Mulvaney K; Kansas University Cancer Center, Kansas City, KS 66205, USA., Shugrue M; Kansas University Cancer Center, Kansas City, KS 66205, USA., Firth-Braun J; Kansas University Cancer Center, Kansas City, KS 66205, USA., Godwin AK; Kansas University Cancer Center, Kansas City, KS 66205, USA; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA., Madan R; Department of Pathology and Laboratory Medicine, Kansas University Medical Center, Kansas City, KS 66160, USA., Phadnis M; Department of Biostatistics, Kansas University Medical Center, Kansas City, KS 66160, USA., Sun W; Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS 66160, USA; Kansas University Cancer Center, Kansas City, KS 66205, USA.
Jazyk:	angličtina
Zdroj:	Cell reports. Medicine [Cell Rep Med] 2023 Feb 21; Vol. 4 (2), pp. 100916. Date of Electronic Publication: 2023 Jan 25.
DOI:	10.1016/j.xcrm.2023.100916
Abstrakt:	This is the phase Ib part of the phase I/II CAMILLA trial evaluating cabozantinib plus durvalumab in advanced chemo-refractory proficient mismatch repair or microsatellite stable (pMMR/MSS) gastrointestinal malignancies including gastric/gastroesophageal junction/esophageal (G/GEJ/E) adenocarcinoma, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). Thirty-five patients are enrolled. There are no observed dose-limiting toxicities during dose escalation. The overall grade 3/4 treatment-related adverse event rate is 34%. Among evaluable patients (n = 30), the objective response rate (ORR) is 30%, disease control rate (DCR) 83.3%, 6-month progression-free survival (PFS) 36.7%, median PFS 4.5 months, and median overall survival (OS) 8.7 months. Responses are seen in 4 of 17, 3 of 10, and 2 of 3 patients with CRC, G/GEJ/E adenocarcinoma, and HCC, respectively. Participants with a PD-L1 combined positive score (CPS) ≥5 have numerically higher ORR, PFS, and OS. Cabozantinib plus durvalumab demonstrates a tolerable safety profile and potential efficacy in previously treated advanced pMMR/MSS gastrointestinal malignancies. Competing Interests: Declaration of interests A.S. reports research grants (to institution) from AstraZeneca, Bristol Myers Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, Daiichi Sankyo, Amgen, Innovent Biologics, Dragonfly Therapeutics, KAHR Medical, and Biontech and advisory board fees from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, and Daiichi Sankyo. R.A.-R. reports research grants (to institution) from AstraZeneca, Bayor, Merck, Bristol Myers Squibb, Exelixis, and Eureka Therapeutics and stock ownership in Actinium Pharmaceuticals and Seagen. A.K. reports research funding (to institution) from Astellas, Tesaro, and Bavarian Nordic. J.B. reports research grants (to institution) from Astellas, Chungchun Intellicrown, Impact Therapeutics, Poseida Therapeutics, Takeda Oncology, and Genome Co. and consultant fees (to institution) from Sanofi. A.K.G. reports research funding from Predicine and VITRAC Therapeutics, is a co-founder of Sinochips Diagnostics, and serves as a scientific advisory board member to Biovica, Clara Biotech, and Sinochips Diagnostics. S.W. reports stock/other ownership in Horizon Therapeutics, Iovance Biotherapeutics, and Merus and institutional research funding from Aleon Pharma, Astellas Pharma, Bayer Health, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Merck Serono, Nektar, Novartis, Pharmacyclics, AbbVie, Regeneron, Rogosin Institute, Sanofi, Seagen, and Sotio. (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu